These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24157181)

  • 21. DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension.
    Catella J; Costes F; Gaultier JB; Court Fortune I; Tulane C; De Magalhaes E; Accassat S; Chomette-Ballereau S; Chapelle C; Bertoletti L
    Respir Physiol Neurobiol; 2020 Aug; 279():103467. PubMed ID: 32464180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of pulmonary hypertension.
    Hoeper MM; McLaughlin VV; Dalaan AM; Satoh T; Galiè N
    Lancet Respir Med; 2016 Apr; 4(4):323-36. PubMed ID: 26975811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary hypertension associated with lung diseases and hypoxemia.
    Cuttica MJ
    Heart Fail Rev; 2016 May; 21(3):299-308. PubMed ID: 27086030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension.
    Berman Rosenzweig E; Barst RJ
    Expert Opin Investig Drugs; 2001 May; 10(5):811-23. PubMed ID: 11322859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening.
    Levy M; Bonnet D; Mauge L; Celermajer DS; Gaussem P; Smadja DM
    PLoS One; 2013; 8(6):e65114. PubMed ID: 23762293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on pulmonary arterial hypertension pharmacotherapy.
    Velayati A; Valerio MG; Shen M; Tariq S; Lanier GM; Aronow WS
    Postgrad Med; 2016 Jun; 128(5):460-73. PubMed ID: 27232660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis.
    Badiani B; Messori A
    Heart Lung Circ; 2016 Jan; 25(1):46-52. PubMed ID: 26233257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Update: Preclinical developments for the treatment of pulmonary arterial hypertension].
    Janssen W; Ghofrani HA; Weissmann N; Grimminger F; Schermuly RT
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S157-9. PubMed ID: 19718604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    Joye R; Lador F; Aggoun Y; Farhat N; Wacker J; Wildhaber BE; Vallée JP; Hachulla AL; McLin VA; Beghetti M
    J Hepatol; 2021 Mar; 74(3):742-747. PubMed ID: 33276028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical therapies for pulmonary arterial hypertension.
    Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
    Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The current pharmacotherapy of pulmonary arterial hypertension].
    Betkier-Lipińska K; Ryczek R; Cwetsch A
    Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
    Park MH
    Catheter Cardiovasc Interv; 2008 Feb; 71(2):205-13. PubMed ID: 18327839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathways in pulmonary arterial hypertension: the future is here.
    Sitbon O; Morrell N
    Eur Respir Rev; 2012 Dec; 21(126):321-7. PubMed ID: 23204120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy adding tadalafil to existing ambrisentan in patients with pulmonary arterial hypertension.
    Hirashiki A; Kondo T; Murohara T
    Hypertens Res; 2014 Jun; 37(6):488-9. PubMed ID: 24646649
    [No Abstract]   [Full Text] [Related]  

  • 36. Eisenmenger syndrome: recent advances in pharmacotherapy.
    Said S; Porres-Aguilar M; Porres-Munoz M; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):289-96. PubMed ID: 24655213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials in group 3 pulmonary hypertension.
    Harder EM; Waxman AB
    Curr Opin Pulm Med; 2020 Sep; 26(5):391-396. PubMed ID: 32657833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension.
    Satoh M; Aso K; Nakayama T; Saji T
    Endocr J; 2017 Dec; 64(12):1173-1180. PubMed ID: 28890480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.
    Frost AE; Badesch DB; Miller DP; Benza RL; Meltzer LA; McGoon MD
    Chest; 2013 Nov; 144(5):1521-1529. PubMed ID: 23907471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].
    Sommer N; Richter MJ; Tello K; Grimminger F; Seeger W; Ghofrani HA; Gall H
    Internist (Berl); 2017 Sep; 58(9):937-957. PubMed ID: 28819824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.